NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax's New U.S. Patent for Enhanced Gedeptin® Gene Therapy in Solid Tumors
TL;DR
GeoVax's new patent through 2045 gives it a competitive edge by protecting its Gedeptin therapy platform for treating multiple solid tumors with localized cytotoxicity.
Gedeptin works as a gene-directed enzyme prodrug therapy using an adenoviral vector to deliver PNP, followed by fludarabine to create localized tumor cytotoxicity while minimizing systemic toxicity.
This therapy offers hope for patients with difficult-to-treat solid tumors like head and neck cancer by providing targeted treatment options with a favorable safety profile.
GeoVax's Gedeptin platform has orphan drug designation and shows synergistic potential with checkpoint inhibitors like Keytruda in upcoming Phase 2 trials for head and neck cancer.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs announced the issuance of U.S. Patent No. 12,453,760, titled 'Enhanced Therapeutic Usage of a Purine Nucleoside Phosphorylase or Nucleoside Hydrolase Prodrug,' which provides composition-of-matter and method-of-use protection for the company's Gedeptin® platform in combination with targeted delivery approaches for solid tumors.
The patent protects the novel application of Gedeptin therapy across multiple solid tumor types, specifically providing protection for the Gedeptin platform in combination with targeted delivery approaches for solid tumors, including head and neck cancer.
The patent extends through 2045, enhancing GeoVax's intellectual property estate for Gedeptin and its use across a range of solid tumor cancers.
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) designed for targeted use in solid tumors. It's delivered via a non-replicating adenoviral vector encoding purine nucleoside phosphorylase (PNP) followed by systemic fludarabine, generating localized cytotoxic activity within tumors while minimizing systemic toxicity.
Key advantages include:
- Localized, tumor-selective cytotoxicity
- Tumor agnostic - expansion potential across multiple solid tumors
- Synergistic potential with checkpoint inhibitors
- Favorable safety profile and orphan drug designation
- Strong patent protection through 2045
GeoVax is preparing for a Phase 2 clinical trial evaluating Gedeptin as a first-line therapy in combination with pembrolizumab (Keytruda®) in resectable head and neck cancer, and additional preclinical programs are assessing Gedeptin across other tumor types including breast and cutaneous cancers.
Gedeptin has received FDA Orphan Drug Designation for oral and pharyngeal cancers and has demonstrated safety and disease control in a multi-center Phase 1/2 trial in patients with advanced head and neck cancer.
The patent issuance marks an important milestone in advancing and protecting GeoVax's oncology pipeline, consolidating the company's leadership in targeted gene therapies and supporting ongoing clinical development plans for difficult-to-treat solid tumors.
Gedeptin is being developed for solid tumors, with specific focus on head and neck cancer (including oral and pharyngeal cancers), and additional preclinical work is assessing its potential across other solid tumors including breast and cutaneous cancers.
GeoVax is a clinical-stage biotechnology company developing both novel vaccines against infectious diseases and therapies for solid tumor cancers, with its lead clinical program being GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials.
Curated from NewMediaWire
